These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 37657881)
21. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464 [TBL] [Abstract][Full Text] [Related]
22. Progress in hepatitis C virus management in chronic kidney disease. Cohen-Bucay A; Francis JM; Gordon CE Curr Opin Nephrol Hypertens; 2021 Sep; 30(5):493-500. PubMed ID: 34054074 [TBL] [Abstract][Full Text] [Related]
23. [Hepatitis B virus and chronic progressive kidney disease]. Kes P; Slavicek J Acta Med Croatica; 2009 Dec; 63(5):397-402. PubMed ID: 20198898 [TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy. Martínez-Campreciós J; Riveiro-Barciela M; Muñoz-Gómez R; Londoño MC; Roget M; Serra MÁ; Escudero-García D; Purchades L; Rodríguez M; Losa-García JE; Gutiérrez ML; Carmona I; García-Samaniego J; Morano L; Martín-Granizo I; Montero-Alonso M; Prieto M; Delgado M; Ramos N; Azancot MA; Rodríguez-Frías F; Buti M Gastroenterol Hepatol; 2023 Oct; 46(8):594-602. PubMed ID: 36584754 [TBL] [Abstract][Full Text] [Related]
25. Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. Kim SM; Song IH Korean J Intern Med; 2018 Jul; 33(4):670-678. PubMed ID: 29961309 [TBL] [Abstract][Full Text] [Related]
26. Direct-acting antivirals and hepatitis B virus (HBV) reactivation in co-infected HBV/HCV kidney-transplant recipients. Pol S; Marion O; Vallet-Pichard A; Meritet JF; Sauné K; Alric L; Kamar N Transpl Infect Dis; 2018 Jun; 20(3):e12864. PubMed ID: 29512231 [TBL] [Abstract][Full Text] [Related]
27. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline. Awan AAY; Berenguer MC; Bruchfeld A; Fabrizi F; Goldberg DS; Jia J; Kamar N; Mohamed R; Pessôa MG; Pol S; Sise ME; Balk EM; Gordon CE; Adam G; Cheung M; Earley A; Martin P; Jadoul M Ann Intern Med; 2023 Dec; 176(12):1648-1655. PubMed ID: 38079642 [TBL] [Abstract][Full Text] [Related]
28. A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. Mazzaro C; Quartuccio L; Adinolfi LE; Roccatello D; Pozzato G; Nevola R; Tonizzo M; Gitto S; Andreone P; Gattei V Viruses; 2021 Nov; 13(11):. PubMed ID: 34835054 [TBL] [Abstract][Full Text] [Related]
29. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study. Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729 [TBL] [Abstract][Full Text] [Related]
31. Hepatitis C virus infection and glomerular disease. Fabrizi F; Donato F; Messa P Minerva Urol Nefrol; 2014 Jun; 66(2):139-49. PubMed ID: 24988205 [TBL] [Abstract][Full Text] [Related]
32. Occult hepatitis B virus infection in hepatitis C virus negative chronic liver diseases. Franzè MS; Pollicino T; Raimondo G; Squadrito G Liver Int; 2022 May; 42(5):963-972. PubMed ID: 35246933 [TBL] [Abstract][Full Text] [Related]
33. Hepatitis B and C virus infection and risk of haematological malignancies. Marrone A; Ciotti M; Rinaldi L; Adinolfi LE; Ghany M J Viral Hepat; 2020 Jan; 27(1):4-12. PubMed ID: 31325404 [TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection. Sterling RK; Sulkowski MS Semin Liver Dis; 2004; 24 Suppl 2():61-8. PubMed ID: 15346248 [TBL] [Abstract][Full Text] [Related]
35. Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection. Chen YC; Li CY; Tsai SJ; Chen YC World J Gastroenterol; 2018 Feb; 24(8):917-928. PubMed ID: 29491685 [TBL] [Abstract][Full Text] [Related]
36. Hepatitis C and renal disease: an update. Meyers CM; Seeff LB; Stehman-Breen CO; Hoofnagle JH Am J Kidney Dis; 2003 Oct; 42(4):631-57. PubMed ID: 14520615 [TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France. Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897 [TBL] [Abstract][Full Text] [Related]
38. HCV and the kidney. Corouge M; Vallet-Pichard A; Pol S Liver Int; 2016 Jan; 36 Suppl 1():28-33. PubMed ID: 26725894 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Li T; Qu Y; Guo Y; Wang Y; Wang L Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]